Introduction and background
Making a molecular genetic diagnosis in current clinical practice relies upon recognition of a characteristic clinical syndrome, ascertainment from available databases whether the syndrome in question has been linked to a known underlying genetic defect, and finally location of a laboratory that can offer diagnostically accredited testing for the gene(s) in question. Assuming such testing is available, the decision whether or not to commission it is based largely on discussion with the patient or parents of the likely clinical utility of testing, which, in turn, is informed by knowledge of the prevalence and clinical penetrance of mutations from previous research reports. When a whole blood sample subsequently arrives in a molecular genetics laboratory, direct sequencing of the candidate disease gene is the most common, though by no means the only, analytic technique. Thus, DNA is extracted from lymphocytes using standard chemical procedures, and in the large majority of cases the search for a genetic mutation explaining the clinical phenotype centres upon highly targeted sequencing of the gene or genes associated with the condition. Conventional sequencing involves amplification of each exon of the targeted gene using specific DNA primers and a polymerase chain reaction (PCR), followed by sequencing of the amplified template fragment using a refinement of the DNA sequencing methodology developed by Fred Sanger more than 30 years ago. 1 This approach to molecular genetic diagnosis is tried, tested and accurate, yielding a confident statement about the presence or absence of mutations in the region sequenced usually in around 8 weeks. However, it is also labour intensive and inefficient when there are many possible genes to sequence. For example, mutations in 14 different genes have been implicated in Bardet-Biedl syndrome, in 10 genes in hypogonadotrophic hypogonadism and in 35 genes in retinitis pigmentosa. 2 -4 Furthermore, it is critically reliant on syndrome recognition at the start of the process, and this may be difficult or impossible where features are atypical or mild. Finally, the precise molecular basis of many genetic syndromes is currently unknown, and up to half of the patients currently receive no molecular diagnosis. 5 Sequencing of the entire human genome in 2001, 6 allied to subsequent major technological advances in DNA sequencing-producing so-called 'next-generation' sequencing (NGS) technology-now promises to transform the laboratory diagnosis of genetic disease. Indeed these technologies have already begun to demonstrate their transformational potential in elucidating novel genetic defects underlying human disease, with subsequent major benefits to clinical diagnostics and care once research findings are translated into clinical tests. However, the glut of genetic information that may now be generated from a single blood sample would pose different risks and new dilemmas were NGS to be directly applied to a patient in a clinical diagnostic setting, raising many areas of scientific uncertainty which are only now beginning to be addressed. These opportunities and challenges will be the focus of this article.
NGS technology
The new generation of sequencing strategies technologies that have been developed and become commercially available over the past few years permits the simultaneous, or 'massively parallel' sequencing of extremely large numbers of DNA templates without the requirement for an equivalent number of target-specific DNA primers, or indeed any knowledge of the target sequence. The various strategies adopted have been reviewed in detail elsewhere. 7 The best developed of the new technologies can sequence of the order of 25 gigabases per day-the equivalent of around 8 complete human genomes. The methods of NGS that have been developed into commercially available platforms are based on cyclic arrays, and are summarized in Figs 1 and 2. They include 454 pyrosequencing, the Illumina platform (Illumina Genome Analyser and HiSeq2000), SOLiD (Applied Biosystems), the Polonator (Dover/Harvard), the HeliScope Single Molecule Sequencer (Helicos), Ion Torrent (Ion Torrent Inc.), PacBio RS (Pacific Biosciences) 7 and outsourced sequencing services such as those provided by Complete Genomics (http://www. completegenomics.com/). There are important differences between each technology, but all share broadly similar key steps.
DNA fragment library generation and amplification
Random fragmentation of DNA into short segments is followed by chemical binding, or ligation, of each fragment to non-specific adaptor DNA sequences. Ligated DNA fragments are either captured on the surface of micron-scale beads with subsequent PCR carried out in Where there is discordance to the reference sequence, its frequency is used to determine if the variant is heterozygous (as here) or homozygous. Reference databases are searched to determine whether variants are novel or previously recognized as SNPs.
E. Raffan and R. K. Semple emulsion (used in 454, Polonator and SOLiD platforms), or alternatively adaptors are tethered to the surface of a solid substrate and amplified using a bridging PCR reaction (used in Illumina sequencing). The point of this step is to amplify single DNA fragments nonspecifically into clusters of clones, thereby amplifying the signal in subsequent sequencing and producing a readable 'library' of overlapping fragments representing the whole of the input DNA (Fig. 1) .
DNA sequencing
The 454 platform uses a method known as pyrosequencing. Beads with attached clonal DNA are distributed across a plate containing picolitre scale wells such that there is only one bead per well. Wells are washed sequentially and repeatedly with a solution containing each of the four deoxyribonucleotides in turn. If the nucleotide is incorporated, light is emitted and recorded such that over hundreds of cycles, the sequence of the DNA template can be progressively built up. Illumina sequencing starts with clusters of clonal DNA fixed on a microchip. Sequencing primers are complementary to the generic adaptor sequences used to tag the DNA fragments before amplification. The reagent solution for extension includes all chain terminating deoxynucleotides, each labelled with a fluorescent tag which corresponds to the base type. After each single base extension, fluorescence is recorded across the four channels. The fluorescent chain terminating tags are then cleaved such that further extension can occur and another cycle started. Over multiple cycles the fluorescence at each cluster is sequentially recorded to build up the linear sequence (Fig. 2) .
Each system has advantages and disadvantages. The 454 platform produces longer sequence reads of in excess of 450 base pairs (bp) than Illumina (up to 100 bp). However, it is currently more expensive (estimated $2 per megabase (Mb) versus $60 per Mb for 454 in one review, 7 although such estimates are rapidly becoming outdated as the technology becomes more widespread). Moreover, where a reference sequence is available as a template for alignment (such as in humans), shorter Illumina reads are adequate. Illumina is prone to substitution errors whereas 454 is most likely affected by artefactual insertions and deletions. Both types of error can cause problems with alignment and mean that variations of interest must be confirmed with conventional Sanger sequencing.
Targeted sequencing of areas of interest
These new technologies permit sequencing of entire individual genomes. As the cost of NGS tumbles, whole genome sequencing is likely to become increasingly popular as a strategy for finding the genetic basis of disease as it offers the potential of finding mutations in areas of the genome (such as regulatory elements or non-coding RNA) that do not code for proteins. However, at present the expense of this makes the targeting of finite resources to sequencing a subset of the genome appealing, and likely to be of most relevance to clinical diagnostics. The subset sequenced might be a chromosomal region linked to disease, 8 a set of genes at different chromosomal loci that have been implicated in a given disease, 9 or all exonic, protein-coding regions of the genome (the so-called 'exome'). This last is of particular interest because the exome constitutes only a very small proportion of the genome-1-1.5% or 30 Mb over 180 000 exons 10 -and yet it is estimated that 85% of mutations causing Mendelian disease lie within it.
Several different technical approaches to selectively abstracting only some regions of the genome for sequencing have been described. 11 The most widely adopted of these for exome capture relies on hybridization of sheared whole genomic DNA to specific oligonucleotides on chip arrays or in solution, and this has been developed commercially and adapted for use with multiple sequencing platforms. 11 Early arrays captured the National Centre for Biotechnology Information consensus coding sequence which contains genes shared between the mouse and human genome; latterly, these have been supplemented with extra exons from genes of potential relevance to disease.
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Areas of agreement
There is no such thing as a 'normal' human genome
In order to interpret genetic data clinically on behalf of a patient, it is essential to have a grasp of genetic variation in a relevant healthy control population. Although a consensus sequence exists for the human genome, every individual harbours many small sequence variants that deviate from this consensus, and these collectively programme many of their unique characteristics. Some of this variation had been catalogued prior to the advent of NGS through conventional sequencing efforts focused on control populations such as the HapMap cohort, and many of the commoner genetic variants, particularly single nucleotide polymorphisms (SNPs), had been assembled into freely available databases such as dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/).
From the initial publication of the sequence of entire human genome, it was clear that healthy individuals also harbour many rarer variants, some of which have been reported to be disease alleles. 13, 14 Since 2009 this early insight has been extended substantially in a rush of publications reporting exomes and genomes sequenced using next-generation technology. Initial reports studied healthy individuals 13, 15, 16 or those affected by Mendelian disorders with a known genetic basis 16 as proof of the concept that exome-wide sequencing can uncover pathogenic allelic variants while exponentially growing numbers of reports now focus on diseases with a suspected but unproven genetic basis.
It has become clear that for every exome sequenced around 20 000-40 000 variations from the reference sequence are seen, with many additional small insertions or deletions that are hard to identify with current data analysis algorithms. A sizable majority of these have been previously reported in many other individuals and are in dbSNP (Fig. 3 ). As will be discussed later, the unmasking of such details of the genetic background of patients, to which clinicians have previously been blind, poses key practical and ethical questions in diagnosis. Viewed more positively, however, such knowledge across many individuals from different populations represents a highly useful resource for researchers and clinicians alike. Thus, as the results of large-scale sequencing projects 17 are archived, an immensely powerful in silico means of assessing genetic variation in particular genes in different ethnicities will be generated. Removing the requirement for experimental sequencing of controls every time a new and possibly pathogenic mutation is discovered will facilitate both research and clinical diagnosis.
NGS can be a powerful tool in investigating Mendelian disease
Historically, finding the cause of Mendelian disease usually relied upon painstaking sequencing of candidate genes, based on knowledge of the Fig. 3 An example of whole exome sequencing data showing the number of variants from the reference sequence identified and how many remain at each filtering step. Missense mutations result in a change in the amino acid sequence. Nonsense mutations are base changes that result in a premature stop codon or nonsense codon, causing the protein product to be truncated and incomplete.
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British Medical Bulletin 2011;99 underlying biology, on linkage studies in families with multiple affected members, or on opportunistic study of patients overlapping chromosomal deletions. However, this approach has severe limitations, especially where no large families are available, and frequently lead to dead ends. NGS now allows researchers to take an unbiased approach to gene discovery, and thus to look for 'unknown unknowns'. This potential has led to intense research activity, and many reports have already emerged of the use of whole exome or whole genome sequencing to elucidate the genetic defect underlying several different genetic disorders whose mechanistic basis had hitherto been unknown (Table 1) .
NGS is particularly powerful in the setting of rare recessive disease in children of consanguineous parents. Here, investigators can focus only on genes where both alleles are affected by the same rare variants. Sometimes, a previously unsuspected disease-causing mutation in a known Mendelian disease gene becomes apparent at this stage 18 -21 and such use of NGS to diagnosis atypical or early clinical presentations is perhaps the most clinical application of NGS at present. In research studies, this approach may even be enough to focus on a single mutation in a previously unsuspected gene, 22 although more often this filtering approach narrows the search to several tens of genes. Additional analytic traction can be gained by looking for commonality among multiple patients from one 23 -29 or more 5,30 -32 families or by combining NGS with genetic mapping. 33 -41 Even with such combined approaches, however, the variant list may be too long to prove the pathogenicity of a given variant using genetics alone, requiring laboratory or animal studies of the biological effect of the variant to prove it is causative. 42, 43 Dominant or sporadic diseases have proven harder to solve using exome sequencing because of the large number of heterozygous variants in any sequenced exome. Despite this, success has come from comparing multiple unrelated patients. 44 -46 Continued refinements of both technology and analytic strategies mean that further major advances in understanding the genetic component of human disease will be made in the coming years, and these will be quickly translated into more conventional, cost-effective and simpler diagnostic tests once the genetic defects are known.
Areas of controversy, problems and pitfalls
Given these successes, the enthusiasm surrounding NGS is understandable. However, as in the deployment of any 'game-changing' technology, insights gained have also revealed new complexity, sometimes challenging old assumptions. This has laid bare the daunting challenge of fully understanding the genetic influences on disease in a research setting, never mind the much more multifaceted undertaking of harnessing the information generated for patient benefit and communicating it effectively. Indeed, although further technical refinements in sequencing can be expected, it is in the interpretation and clinical use of the genetic data generated, with the attendant far reaching societal and ethical implications, that the thorniest problems lie.
Too much information? Blurring the boundaries of Mendelian disease
The Mendelian model of genetic disease has had immense utility in guiding clinical management and genetic counselling. This prognostic value is attenuated in some conditions, however, by the phenomenon of variable penetrance (the variable tendency of genetic mutations to translate into clinical disease). This is usually ascribed either to environmental factors or to unspecified 'genetic modifiers'. Even in the pre-NGS era detailed genetic studies of mutations in known 'Mendelian' disease genes have produced many examples of broad phenotypic spectra associated with mutations in the same gene, often conferring disease with different Mendelian patterns of inheritance. Furthermore, some examples of pathogenic interactions between mutations in different genes have been described. 4, 47 Indeed, it has been argued that the whole construct of 'Mendelian' disease is artefactual, usually based on the initial description of severe or classical cases, and that such deviation from truly Mendelian inheritance may be common. 47 Although these ideas have been widely discussed, genetic tools in the pre-NGS era were relatively blunt in uncovering multiple mutations in different genes, and it is only with the advent of NGS that the entire genetic architecture of an individual patient is suddenly accessible. While this quantum leap is powerful from the point of view of genetic research, the tools necessary to analyse and understand such far reaching genetic data lag far behind the technical ability to generate them, which poses major challenges for clinical diagnosis.
Even where a single disease-causing mutation does exist, discriminating it from the thousands of other single nucleotide variants identified on each exome or genome sequenced may be extremely exacting. Variants which appear in dbSNP or in many control exomes and genomes 17 are usually deemed unlikely to be the cause of rare Mendelian diseases and can be ignored. Even so, several thousand variants usually remain. Of these, around 300-400 are confidently predicted to alter protein structure. 17 The primary challenge for those interested in disease is to distinguish between background polymorphisms and pathogenic mutations. Various approaches have been used to identify the cause of previously unsolved genetic diseases, depending on the patients studied and the mode of inheritance. 48 Filtering against control genomes to identify novel/rare variants has been shown to be a powerful tool in the search for a putative causative variant. However, particularly when studying patients from the Middle East and the Indian subcontinent, control populations are rarely well matched. This means that common variants in the subject population may be deemed 'novel' when compared with inappropriate controls. Family genotyping can help rule out some variants but some may remain candidates. Conversely, the availability of an increasing number of control exomes risks that a pathogenic variant is erroneously filtered. For instance, a very rare, highly penetrant, autosomal recessive condition affecting 1 in 4 000 000 people implies a minor allele frequency in the general population of 1 in 1000. As the number of control exomes exceeds 1000 there is a high chance that removing all variants which have been previously recorded would result in missing the causative gene.
When the concept of oligogenic disease or significant genetic modifiers of a Mendelian phenotype is added to the mix, it becomes clear that it is extremely difficult in an individual patient confidently to link a disease to only one or two mutations. The learning curve of the clinical genetic community will doubtless be steep in assimilating these ideas into clinical practice, however for the time being this type of genetic approach belongs more properly in the realm of research.
For the above reasons, it is likely that in the medium term, clinical benefit of NGS will come not from the rapid introduction of personal genome sequencing, but rather from an increased rate of disease gene discovery allied to the ability to rapidly sequence multiple genes at once. Where only one gene is implicated in a disorder, conventional capillary sequencing can then be performed as previously. This remains slow, however, so it is likely that diagnostic laboratories will offer NGS of patient DNA that has been hybridized to a custom-designed array designed to capture multiple candidate genes which could cause a given clinical presentation. Along with the ability to run multiple patient samples at once, this may revolutionize genetic diagnostic testing.
Social and ethical implications of NGS
Every genome sequenced is heterozygous for 50 -100 variants classified by the Human Gene Mutation Database as causing inherited disorders 10 and often has many more functional homozygous or heterozygous novel variants in genes implicated in Mendelian disease. 17 In
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British Medical Bulletin 2011;99 other words, whatever the suspected genetic disease being investigated, and even if the causative mutation is convincingly identified, information will be generated regarding a large number of other genetic variants that are known or suspected to be pathogenic, and that may confer risk of future, unrelated disease. Compounding this further will always be some genotyping errors, and some of these 'pathogenic' mutations will have been misclassified as a cause of disease in the first place. Indeed a recent study showed that 27% of a wide selection of HMGD entries were actually common polymorphisms or misannotated. 49 For these reasons, any patient giving consent to the use of NGS must be carefully counselled about the potential of the technology to reveal information that may be relevant to their risk of future disease, and understand how this information will be handled. These issues have yet to be subject to widespread scrutiny in the clinical diagnostic arena, although the necessary studies are currently underway. However, in a research setting the rapid adoption of NGS for use in human volunteers has necessitated careful consideration of key questions. What feedback should research subjects receive about the contents of their genomes? Does the researcher have an obligation to search for potentially clinically relevant findings in every genome? If they are found, should the research subject be told? What constitutes informed consent for research participants? Who 'owns' NGS data and who should have access to it?
These questions have been addressed in the preparation of the ethical governance framework for one large research study employing whole genome and whole exome sequencing-the UK10K project (http://www.uk10k.org/ethics.html). This pragmatic working approach to ethical issues around the use of NGS in human research enshrines certain principles. It was first agreed that any mutation believed to account for the disease being studied should be communicated to the patient after due validation, and used to guide possible treatment and genetic counselling. More challenging was the handling of mutations discovered that are not relevant to the presenting disease or that are found in a healthy individual, but may point to future or occult disease, or have implications for reproductive decisions. For the purposes of the UK10K project, it was made clear that researchers do not have an obligation to seek out such incidental findings for, among other considerations, such an obligation would dramatically impede researchers' ability to focus on addressing the particular disease state being studied. It was nevertheless suggested that where potentially clinically important mutations are identified, the genotype should be validated by an accredited diagnostic laboratory, and the clinical validity (whether the results are of consistent clinical significance) and clinical utility (whether knowledge of the results is likely to benefit the patient) carefully considered in conjunction with a clinical geneticist. Whatever the particular position adopted by individual research teams, it is clear that the consent gained must be truly informed, with explicit statements incorporated about handling genetic information in these different scenarios.
This approach to using NGS in human research volunteers represents a starting position, arrived at after multidisciplinary deliberations, and it is expected to evolve as experience grows. Generating guidelines for the clinical diagnostic use of NGS is likely to be more complex still. This may be sufficient to tempt clinicians to eschew diagnostic use of NGS until more of the underlying genetic and ethical issues are clarified. However, as the cost of exome and genome sequencing tumbles, and as the era of widely available and possibly largely unregulated direct to consumer testing is ushered in, dealing with exome-wide genetic data for individual patients may be thrust upon them. The challenges, opportunities and risks involved have been well reviewed.
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Areas timely for developing research Faster, deeper, longer-the technical quest for accurate data Technological research will continue to deliver improvements in sequence quality, alignment, data management and the ability to multiplex samples. Concurrently, the cost of sequencing is tumbling such as we are fast approaching the era of the $1000 human genome sequence, a figure hard to imagine a decade ago when the completion of a single human genome sequence generated such excitement. 6 Today's sequencing has progressed from that available just a year ago. Faster technology allows more sequencing reads per sample, increasing the depth of coverage (the number of amplified fragments at each base position) and the likelihood of identifying a variant at each site and calling it correctly. Each base call is the product of a complex set of DNA library preparation and sequencing reactions leading to millions of fragments of sequence which must be aligned to each other and the reference sequence before making a call as to the statistical likelihood of each base occurring at that position. Of course, not all variation is due to base substitution; structural variations such as copy number variations, inversions and translocations are important in many diseases. These are particularly challenging to align and annotate. 52 Longer and paired-end reads aid those processes but they remain difficult and a weak point in the process of finding the genetic variants responsible for disease.
Mendelian disease
In most successful reports so far, researchers have compared multiple similar patients or family members to focus on the causative mutation. However, sometimes phenotypically similar patients are genotypically disparate, meaning a common gene or variant cannot be found, while in other familial cases more than one variant may co-segregate with disease. In either case, how is the pathogenic mutation to be identified? More control genomes will help (see below) but inventive functional biology studies are likely to be the key to proving a proposed variant to be causative. Despite these challenges, NGS seems set to rejuvenate the search for a genetic cause in some syndromes where painstaking linkage studies and candidate gene screening formerly lead to dead ends. By taking an unbiased approach to gene discovery, we are likely to learn much of value in terms of the molecular biology of health and disease, with the prospect of revealing new therapeutic targets.
Although exome sequencing has predominated thus far in an effort to save time and money, it is also likely eventually that diagnostic sequencing may extend beyond the confines of the exome in an attempt to solve the genetic basis of disease in the 15% of patients who do not have coding sequence mutations. 10 In such cases, mutations may lie in promoter regions of introns, in genes encoding small nucleolar RNA or microRNA molecules which can play an important role in posttranscriptional regulation or at sites of epigenetic regulation. However there is a huge amount to be learnt about these complex areas of genetics before proving pathogenicity of mutations in such regions becomes diagnostically tractable.
Population genetics
As discussed, knowledge of genetic variation within the healthy population is central to identifying pathogenic variants. Initial efforts at mass sequencing of control exomes and genomes have not reported phenotypic data. At present the numbers involved are small enough that the chance of unwittingly removing a genuinely pathogenic variant by ignoring those present in the controls is small. However, over time that chance will increase and there will be an increasing demand for phenotypic information on control populations.
Different ethnic groups are likely to have different degrees of variation and different specific variants. This has been addressed in the 1000 genomes project by including subjects of European ancestry from Utah, Han Chinese from Beijing, Japanese individuals from Tokyo and Yoruba from Ibadan, Nigeria. However, the Middle East and Indian subcontinent are examples of regions containing ethnic groups poorly represented thus far. Given that genetic disease does not respect such formal ethnic and geographical boundaries, there will be an increasing need for more and more varied control genomes to be sequenced.
Complex traits
The use of NGS to investigate the genetics of complex traits diseases-that is, diseases which appear to have some underlying genetic basis but which do not conform to traditional Mendelian recurrence patterns-is in its infancy. In recent years, genotyping arrays which profiled thousands of common SNPs have been used in genome-wide association studies (GWAS) to investigate the genetic cause of many complex diseases. Despite early promise, the associations found have, in the main, only explained a tiny fraction of the true genetic variance in common disease. This has led to speculation that very rare variants are responsible for much of human variation and complex disease susceptibility.
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NGS proffers the potential of opening up the entire spectrum of genomic alterations for the genomic analysis of complex traits. 54 Alongside, there will be formidable challenges related to the deep phenotyping and high numbers of subjects required for GWAS studies, but as the focus of NGS studies increasingly moves from the 'boutique', very likely monogenic conditions to commoner disorders with a likely oligogenic basis, there will be increasing need to address them.
The power of NGS to efficiently sequence massive amounts of DNA has already been used to unlock the secrets of previous GWAS results; Nejentsev et al. used NGS to resequence a number of candidate genes in a large number of affected and control patients and were able to focus on IFIH1 as the most likely causative gene in a region previously linked to disease by GWAS. 55 
Neonatal screening
Bell et al. 49 recently simultaneously sequenced 7717 regions from 437 target genes known to be associated with HMGD disease in multiple samples, using methods that might in future be applicable to a population-wide screening programme. They pointed out that although the cost is significant, it could be far outweighed by the social and cost benefits of avoiding severe recessive childhood disorders. For preconception screening to be of use, however, antenatal diagnosis is often required. In another study, investigators made use of the fact that 10% of DNA found in maternal plasma is of foetal origin. They performed exome-wide sequencing on maternal, paternal and maternal plasma DNA. They demonstrated that the entire foetal genome is present in maternal plasma and by 'subtracting' maternal and paternal genotypes from the plasma DNA sequence, they were able to infer the mutational status of the unborn foetus for a disease of known risk. 56 
Conclusions
NGS will tremendously facilitate the reach and power of traditional genetic approaches to discovering disease genes, and is likely enormously to accelerate the rate of identification of genes causing rare and severe Mendelian disease. It should also ultimately decrease the number of patients with apparently novel genetic syndromes who remain without diagnosis by permitting identification of atypical presentations of known disease or superimposed diseases. In addition, it is likely to lead to better understanding of the pathogenesis of cancer and suggest new ways of targeting treatment.
However, both physicians and genetic counsellors will have to redefine their understanding of genetic risk in the light of new information. Perhaps the greatest challenge comes from the surfeit of genetic data garnered in healthy individuals, sometimes via direct to consumer genetic testing. There is a significant attendant risk of producing net harm, or increasing the number of 'worried well', at least until the prognostic significance of individual genotypes, and the nature of interactions between genotypes, becomes more fully understood. Addressing these issues will require the research community to lead a wider societal discussion about the use of NGS.
